Cargando…
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely on CDK4 function, and are exquisitely sensitive to CDK4/6i. In contrast, tumor cells expressing both CDK4 and...
Autores principales: | Wu, Xuewei, Yang, Xiaobao, Xiong, Yan, Li, Ruitong, Ito, Takahiro, Ahmed, Tamer A., Karoulia, Zoi, Adamopoulos, Christos, Wang, Hong, Wang, Li, Xie, Ling, Liu, Jing, Ueberheide, Beatrix, Aaronson, Stuart A., Chen, Xian, Buchanan, Sean G., Sellers, William R., Jin, Jian, Poulikakos, Poulikos I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462800/ https://www.ncbi.nlm.nih.gov/pubmed/34568836 http://dx.doi.org/10.1038/s43018-021-00174-z |
Ejemplares similares
-
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
por: Ahmed, Tamer A., et al.
Publicado: (2019) -
CDK4: a master regulator of the cell cycle and its role in cancer
por: Baker, Stacey J., et al.
Publicado: (2022) -
The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019) -
Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020) -
CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)